Table 3

Adherence* to DAAs among OAT patients in Norway between 2013 and 2017

AdherentNon-adherentTotal
Adherence by gender, n (%)
 Male551 (67)277 (33)828
 Female191 (67)92 (33)283
 Total742 (67)369 (33)1111
Adherence by age, n (%)
 18–35119 (58)85 (42)204
 36–45259 (68)122 (32)381
 46–55302 (70)128 (30)430
 >5662 (65)34 (35)95
 Total742 (67)369 (33)1111
Adherence by OAT medication, n (%)
 Methadone/levomethadone298 (65)157 (35)455
 Buprenorphine based444 (68)212 (32)656
 Total742 (67)369 (33)1111
Logistic regression on factors associated with adherence*
aOR (CI 95%)P value
Age0.98 (0.97 to 1.00)0.17
Gender
 Male1.00
 Female0.92 (0.69 to 1.23)0.57
OAT continuity
 Category I: ≥2 DDD1.00
 Category II: 1–2 DDD1.36 (1.02 to 1.82)0.035
 Category III: <1 DDD1.36 (0.93–1.99)0.11
  • *Adherence defined as collected ≥3 prescriptions and >84 DDDs (unless ledipasvir and sofosbuvir which also calculated as ≥2 prescriptions and >56 DDDs). Analyses included 1111 patients as inclusion were ceased 01.10.17 to avoid counting treatment initiation after this date non-adherent.

  • DAA, direct-acting antivirals; DDD, daily defined doses; NorPD, Norwegian Prescription Database; OAT, opioid agonist therapy.